Johnson & Johnson (JNJ.MX)

3,037.00

-51.00

(-1.65%)

At close: April 24 at 1:41:16 PM CST

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 13 hours ago

JNJ
3 Dividend Kings That Have Raised Their Payouts in 2025

If you want to collect a lot of dividend income, it's important to focus on more than just a stock's current yield. Stocks that consistently grow their payouts over the years can be far more valuable investments to hang on to because that can ensure your dividend income is rising, possibly at a higher rate than inflation. Three stocks which have impressive track records for dividend growth are Walmart (NYSE: WMT), Johnson & Johnson (NYSE: JNJ), and Procter & Gamble (NYSE: PG).

Motley Fool 13 hours ago

WMT

PG

JNJ
In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now

Short-term tariff uncertainty marks the perfect opportunity for long-term investors to snag some amazing deals.

Motley Fool 18 hours ago

JNJ

^GSPC

SIRI
Jim Cramer on Johnson & Johnson (JNJ): ‘A Good Quarter — Market Finally Cares’

We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the […]

Insider Monkey yesterday

JNJ
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks yesterday

JNJ
European pharma companies push for higher drug prices in EU amid U.S. tariff threats

(Reuters) -European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, the bloc would fall further behind the U.S., where tariff threats have triggered a wave of pharma investment announcements. AstraZeneca Chief Executive Officer Pascal Soriot said that just like Europe has stepped up its defense spending, it now must do the same and invest more to protect its health sovereignty amid a shifting world order. "Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk," Soriot said in a statement.

Reuters yesterday

NVS

SNY

JNJ
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.

StockStory yesterday

JNJ
Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Johnson & Johnson, Chevron, and Flowers Foods have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 3% to 5%. Johnson & Johnson Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. Don't Miss: Delo

Benzinga 2 days ago

CVX

JNJ

FLO
Johnson & Johnson (NYSE:JNJ) Showcases Paradigm-Shifting Bladder Cancer Trials at AUA 2025

Johnson & Johnson (NYSE:JNJ) recently announced upcoming presentations at the AUA Annual Meeting, showcasing promising developments in its oncology pipeline, particularly therapies TAR-200 and TAR-210, which could have impacted its stock by highlighting innovative advances. During the last quarter, J&J's share price moved up 5.92%, amid a broader market upswing driven by strong trading sessions like the Dow Jones' 1,000-point surge. The company’s efforts in enhancing its dividend by 4.8% and...

Simply Wall St. 2 days ago

JNJ
Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.30

The board of Johnson & Johnson ( NYSE:JNJ ) has announced that the dividend on 10th of June will be increased to $1.30...

Simply Wall St. 2 days ago

JNJ
Johnson & Johnson (JNJ): Buy, Sell, or Hold Post Q1 Earnings?

Johnson & Johnson has been treading water for the past six months, recording a small loss of 3.8% while holding steady at $157.30. However, the stock is beating the S&P 500’s 11% decline during that period.

StockStory 2 days ago

JNJ
Is Johnson & Johnson (JNJ) the Best American Dividend Stock to Buy According to Analysts?

We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by delivering consistent and solid returns. During periods of economic […]

Insider Monkey 3 days ago

JNJ
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder can

PR Newswire 3 days ago

JNJ
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges

Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.

Zacks 3 days ago

UNH

LLY

JNJ
Is Johnson & Johnson (JNJ) the Best Low Volatility Stock to Buy Now?

We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first quarter of 2025, marked by increased volatility […]

Insider Monkey 4 days ago

JNJ
2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government

In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poor's) downgraded the long-term credit outlook of the United States from its highest designation of AAA to AA+, citing budgetary issues. High credit ratings are not just handed out. In fact, only two U.S.-based companies maintain the coveted AAA rating from S&P. They may be a good place for investors to park cash as President Donald Trump attempts to shake up the global trade order with sweeping tariffs -- a situation that could turn into a long-lasting trade war if negotiations are not soon reached.

Motley Fool 4 days ago

JNJ

MSFT
From $50 A Month To $1M Portfolio — Investor Shares Top 10 Holdings, Says 'Finally Reached $1M!' Thanks To Relentless Discipline

Building wealth through dividends isn’t an overnight success, but rather work that requires relentless discipline, patience, consistency, and the power of compounding. While many chase quick gains, the real magic happens when investors commit to a long-term strategy, reinvesting dividends and steadily growing their portfolios over decades. One investor’s recent milestone proves just that: a $1 million portfolio generating $4,000 a month in passive income, all starting from humble beginnings of j

Benzinga 5 days ago

ARCC

JNJ

MO
Johnson & Johnson (JNJ): Among Value Stocks in Ken Fisher’s Portfolio

We recently published a list of 10 Value Stocks in Ken Fisher’s Portfolio. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other value stocks in Ken Fisher’s portfolio. Trump’s “stupid” tariffs will fail; that’s the sentiment echoed by billionaire investor Ken Fisher as their impact […]

Insider Monkey 5 days ago

JNJ
3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now

Dividend stocks can be fantastic investments. The best ones pay an attractive and growing stream of dividend income while also delivering healthy stock price appreciation over the long term. While there are lots of dividend stocks out there, Johnson & Johnson (NYSE: JNJ), Invitation Homes (NYSE: INVH), and NextEra Energy (NYSE: NEE) are three of the best.

Motley Fool 5 days ago

JNJ

NEE-PT

INVH
Jim Cramer on Johnson & Johnson (JNJ): Tariff-Proof, Drug-Driven, and Still a Buy

We recently published a list of Jim Cramer Sees Opportunity in Pessimism and Highlights These 12 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer pushed back against […]

Insider Monkey 6 days ago

JNJ

Performance Overview

Return	JNJ.MX	S&P 500 (^GSPC)
YTD	+1.04%	-6.75%
1-Year	+20.05%	+8.15%
3-Year	-17.46%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Survey

Johnson & Johnson (JNJ.MX)

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

3 Dividend Kings That Have Raised Their Payouts in 2025

In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now

Jim Cramer on Johnson & Johnson (JNJ): ‘A Good Quarter — Market Finally Cares’

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

European pharma companies push for higher drug prices in EU amid U.S. tariff threats

JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations

Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income

Johnson & Johnson (NYSE:JNJ) Showcases Paradigm-Shifting Bladder Cancer Trials at AUA 2025

Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.30

Johnson & Johnson (JNJ): Buy, Sell, or Hold Post Q1 Earnings?

Is Johnson & Johnson (JNJ) the Best American Dividend Stock to Buy According to Analysts?

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges

Is Johnson & Johnson (JNJ) the Best Low Volatility Stock to Buy Now?

2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government

From $50 A Month To $1M Portfolio — Investor Shares Top 10 Holdings, Says 'Finally Reached $1M!' Thanks To Relentless Discipline

Johnson & Johnson (JNJ): Among Value Stocks in Ken Fisher’s Portfolio

3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now

Jim Cramer on Johnson & Johnson (JNJ): Tariff-Proof, Drug-Driven, and Still a Buy

Performance Overview